"Lifting Pill" chloroba occupies!The first prescription in the country has been opened

As the original research medicine that was temporarily imported by clinical needs for clinical urgently needed medicines, clotal Zhan recently issued the first prescription in the country at the Beijing Union Hospital. This is a drug that treats children with rare and difficult epilepsy. It can be said to be a "life -saving medicine" for the treatment of such diseases. According to the news, the first domestic medicine for the treatment of related diseases has been approved recently. How is its price? Can it meet the needs of patients?

The family members of children say that they can prescribe medicine

Cobra is a drug for rare cure for children with epilepsy, which plays a very important role in adjuvant therapy. However, because chipuba occupies the second type of psychotropic drugs in my country and is addictive, it has not been approved in China before.

In order to meet the patient's demand for a small amount of specific clinical urgently needed drugs that have been listed abroad and have no supply in China, in June of this year, the State Health and Health Bureau and the State Drug Administration jointly formulated and released the "clinical urgent need for temporary imports of drugs for drugs. "And" Cobra Temporary Import Work Plan ". The "Plan" states that the imports of desertzhan will be implemented one after another at 50 third -level hospitals across the country in Beijing Union Hospital. Children and their families can buy chorica through eligible doctors.

Recently, the Beijing Union Hospital opened the first chlorba cubes in the country. Ms. Mao's son was the first child to use the original drug chinenia after prescribing prescriptions in domestic hospitals.

Ms. Mao's son suffered from baby spasm at the age of two. She has been taking chrysea for nearly 5 years. She has been purchasing from abroad by friends, and often faces the risk of drugs. Ms. Mao said that if such diseases cannot be taken for a long time, it is easy to repeat and even bring complications.

Provide a solution to the availability of other rare diseases

Zhang Bo, director of the Department of Pharmacy Department of Peking Union Hospital, said that the impact is very serious in terms of children or families. "For example, the impact on the intellectual development of the child, the damage to his body, and the mental stress are very great."

Zhang Bo pointed out that with the import of chloropa occupation of the original drug, the problem of drug use of drugs in domestic refractory epilepsy has been effectively relieved, and it provides a solution for the availability of other rare diseases.

Shao Rong, Executive Dean of the Academy of Pharmaceutical Supervision Science of China Pharmaceutical University, said that the measures to solve the problem of rare disease families mainly include imported original drugs, localization of imported drugs, and imitation. According to Shao Rong, the registration and approval of imported drugs need to go through multiple strict procedures. In recent years, for rare disease medications, the state drug supervision department also reduces the time of listing approval as much as possible while strictly benefiting the risk benefits. Patients and families saw the dawn as soon as possible.

Shao Rong said that directly imported medicines from abroad, that is, products listed abroad, drug holders are interested in coming to the Chinese market and applying to the drug supervision bureau. Pathopathy, surrounding children's medication, its procedures will be appropriately accelerated. "It depends on how its clinical data is, whether there are data differences, etc., and it will also involve the problem of rare disease samples. It depends on the number of samples if there are clinical research? However, this kind of this type The approval of drugs is relatively flexible under the premise of ensuring safety. "

The price is cheaper than imported medicine

In addition, the first domestic medicine for the treatment of related diseases has been approved recently. Liao Zongquan, deputy director of the enterprise development center, said, "In September, we obtained the" (Drug) Registration Certificate "approved by the State Drug Administration and obtained our production approval. Our company is expected to be listed in October in October."

Liao Zongquan revealed that there are relatively few drug audiences used in such rare diseases. There are not many companies engaged in R & D and production in China, and it is not difficult.

“精神管制类药品的研发相对于普药研发，在管理环节要求更多，不管是物料，还是实际生产等各个环节，都有一些特殊的要求，比如要求双人操作等各方面。”廖宗权表示， For the price issues that everyone pays attention to, the company has not finally determined the sales price, but it is certain that it will definitely be cheaper than imported drugs. According to Xinhuanet

- END -